ABHD6

Across TCGA pan-cancer cohorts, ABHD6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABHD6 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ABHD6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where ABHD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.306	0.853	.001	24	view →
UCEC	DFS	Quartile	III,IV	0.328	1.000	.042	8	view →
HNSC	OS	Median	All	1.000	0.959	.023	6	view →
GBM	DFS	Median	All	0.589	0.764	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ABHD6–LUAD (OS)

Open the LUAD breakdown →